Disclosed herein are genetically engineered hematopoietic cells, which express one or more Krebs cycle modulating polypeptides, and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered hematopoietic cells for inhibiting cells expressing a target antigen in a subject in need thereof.

Provided are an engineered strain for synthesizing a dibasic organic acid and preparation and application of same. The engineered strain introduces or up-regulates expression of a positive regulator gene for synthesis of a dibasic organic acid, and/or down-regulates expression of a negative regulator gene for synthesis of a dibasic organic acid, as compared with the origin strain of the engineered strain, the producing capability for producing the dibasic organic acid is improved. The dibasic organic acid comprises malic acid, succinic acid, fumaric acid, oxaloacetic acid, glutaric acid, and adipic acid; the expression product of the positive regulator gene comprises aspartate aminotransferase, glutamic acid-aspartate transporter, C4-dicarboxylic acid transporter, pyruvate carboxylase and malate dehydrogenase, glucose transporter; the expression product of the negative regulatory gene comprises succinyl-CoA synthase, and malic acid-alpha ketoglutarate transporter, and the original strain comprises myceliophthora thermophila, thielavia terrestris, aspergillus, and rhizopus.

Disclosed herein are genetically engineered hematopoietic cells, which express one or more Krebs cycle modulating polypeptides, and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered hematopoietic cells for inhibiting cells expressing a target antigen in a subject in need thereof.

Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2,6-dimethyl-Tyr-D-Arg-Phe-Lys-NH.sub.2, Phe-D-Arg-Phe-Lys-NH.sub.2, or D-Arg-2,6-Dmt-Lys-Phe-NH.sub.2.

Live attenuated bacteria vaccines against enteric septicemia of fish, especially catfish, and methods related to the same. Mutant strains of the bacteria Edwardsiella ictaluri (a pathogenic bacterial strain of Enterobacteriaceae) are provided. The mutant Edwardsiella ictaluri bacteria (or other pathogenic bacterial strain of Enterobacteriaceae) contain one or more gene deletions or disruptions that result in less virulent bacterial strains as live attenuated vaccine compositions against virulent wild-type Edwardsiella ictaluri bacteria (or other pathogenic bacterial strain of Enterobacteriaceae). The mutant strains showing the best immunological protection and safety as a vaccine are the triple mutants ESC-NDKL1 (gcvPsdhCfrdA) strain and ESC-NDKL2 (gcvPsdhCmdh) strain, with the ESC-NDKL1 strain providing the greatest safety and efficacy of these two triple mutants.

The present disclosure provides for production of succinic acid from organic waste or biogas or methane using recombinant methanotrophic bacterium. In one embodiment, the recombinant methanotrophic bacterium includes exogenous nucleic acid(s) or gene(s) encoding for specified enzymes. In a further embodiment, succinic acid producing capacity of the recombinant methanotrophic bacterium is increased above the basal level by overexpression or/and downregulation of selected gene(s). In another embodiment, a process of producing succinic acid using the recombinant methanotrophic bacterium is disclosed. The present invention successfully solves the problems in converting organic waste to a useful chemical thereby providing an environment-friendly and commercially viable solution for waste management.

The present application provides genetically modified yeast cell comprising an active succinate fermentation pathway, as well as methods of using these cells to produce succinate.

The present invention is inter alia concerned with a method of diagnosing Alzheimer's disease in a patient, wherein said method is based on determining the amount of at least one premature mitochondrial protein. Further, the present invention relates to the use of such a protein as marker for Alzheimer's disease. Accordingly, antibodies binding to such a preprotein may be used for diagnosing Alzheimer's disease. The present invention is based on the finding that premature mitochondrial proteins accumulate in Alzheimer's disease.

Disclosed herein are methods and compositions for targeted modification of one or more endogenous plant malate dehydrogenase genes.

The present application provides genetically modified yeast cell comprising an active succinate fermentation pathway, as well as methods of using these cells to produce succinate.